Side effect frequencies are typically higher in the weight management indication (Zepbound) compared to the diabetes indication (Mounjaro), particularly at higher doses
doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Results were reported as the quantity of NADH oxidized per milligram of protein and as a percentage in comparison to the control group (Alhowail et al., 2022)
AlixPartners research found that 85% of consumers buying holistic beauty products want detailed ingredient information
associated with heart disease
Simpson said she felt "forced" into talking publicly about her weight loss after a photo with two of her children she posted on social media sparked headlines about Ozempic